Bristol-Myers Squibb Co  

(Public, NYSE:BMY)   Watch this stock  
Find more results for bmy
-0.54 (-0.76%)
After Hours: 70.50 -0.19 (-0.27%)
May 25, 7:40PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 70.54 - 71.57
52 week 51.82 - 73.06
Open 71.30
Vol / Avg. 0.00/5.85M
Mkt cap 119.39B
P/E 75.51
Div/yield 0.38/2.15
EPS 0.94
Shares 1.66B
Beta 0.53
Inst. own 75%
Jul 21, 2016
Q2 2016 Bristol-Myers Squibb Co Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 4, 2016
Bristol-Myers Squibb Co to Discuss ASCO Highlights - 7:00PM EDT - Add to calendar
May 4, 2016
Bristol-Myers Squibb Co at Deutsche Bank Health Care Conference
May 4, 2016
Bristol-Myers Squibb Co Annual Shareholders Meeting (Estimated)
May 3, 2016
Bristol-Myers Squibb Co Annual Shareholders Meeting
Apr 28, 2016
Q1 2016 Bristol-Myers Squibb Co Earnings Call
Apr 28, 2016
Q1 2016 Bristol-Myers Squibb Co Earnings Release
Mar 31, 2016
Bristol-Myers Squibb Co at William Blair Health Cancer Immunotherapy: A Long-Awaited Reality Conference
Mar 16, 2016
Bristol-Myers Squibb Co at Barclays Global Healthcare Conference
Mar 7, 2016
Bristol-Myers Squibb Co at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 27.47% 9.85%
Operating margin 37.58% 8.57%
EBITD margin - 16.27%
Return on average assets 15.20% 4.98%
Return on average equity 33.46% 10.75%
Employees 25,000 -
CDP Score - 100 C


NEW YORK, NY 10154
United States - Map
+1-212-5464000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in BioPharmaceuticals segment. Its pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics. Its small molecule drugs are administered orally in the form of a pill or tablet. Its biologics are administered to patients through injections or by infusion. It offers products in a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in over six foreign countries.

Officers and directors

Giovanni Caforio M.D. Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Charles A. Bancroft Chief Financial Officer, Executive Vice President
Age: 56
Bio & Compensation  - Reuters
Louis S. Schmukler President - Global Manufacturing and Supply
Age: 60
Bio & Compensation  - Reuters
Francis M. Cuss Executive Vice President, Chief Scientific Officer
Age: 61
Bio & Compensation  - Reuters
Sandra Leung Executive Vice President, General Counsel and Corporate Secretary
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul von Autenried Senior Vice President - Enterprise Services, Chief Information Officer
Age: 54
Bio & Compensation  - Reuters
Anne Nielsen Senior Vice President, Chief Compliance and Ethics Officer
Age: 55
Bio & Compensation  - Reuters
Joseph C. Caldarella Senior Vice President, Corporate Controller
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ann Powell Judge Senior Vice President - Global Human Resources
Age: 50
Bio & Compensation  - Reuters
John E. Elicker Senior Vice President - Public Affairs
Age: 56
Bio & Compensation  - Reuters